NDV-01 (sustained-release gemcitabine-docetaxel)
Phase 3RecruitingDevelopment Stage
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer
Jun 1, 2026 → Sep 1, 2032
About NDV-01 (sustained-release gemcitabine-docetaxel)
NDV-01 (sustained-release gemcitabine-docetaxel) is a phase 3 stage product being developed by Relmada Therapeutics for Bladder (Urothelial, Transitional Cell) Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07464145. Target conditions include Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder.
What happened to similar drugs?
20 of 20 similar drugs in Bladder (Urothelial, Transitional Cell) Cancer were approved
Hype Score Breakdown
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07342517 | Phase 3 | Withdrawn |
| NCT07464145 | Phase 3 | Recruiting |
| NCT07313891 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Bladder (Urothelial, Transitional Cell) Cancer